- With the new facility, Hetero aims to boost its sterile pharmaceutical manufacturing capabilities, along with biosimilars and biologics production, while generating 2000 new jobs.
Hyderabad, October 17, 2022: Hetero, India’s leading pharmaceutical company with the widest global reach, today announced the acquisition of a brownfield manufacturing plant at Penjerla located in Telangana, India. The facility spread across 55.27 acres, will be Hetero’s flagship sterile pharmaceutical and biologics manufacturing unit, bolstered by state-of-the-art technology.
The acquisition reinforces Hetero’s renewed commitment to expand its reach and capabilities in order to respond with agility to the world’s evolving health needs and produce high-quality and affordable medicines.
Dr. Vamsi Krishna Bandi, Managing Director, Hetero, said: “We are committed to an investment upwards of US$75 million, (approximately INR 600 Cr) to upgrade and enhance existing facilities at the site and expand manufacturing of our global biologics and sterile pharmaceutical products.”
With this facility, Hetero aims to add 2000 new jobs in biochemistry, pharmaceutical sciences, molecular biosciences, engineering, and ancillary services.
PwC acted as the exclusive financial advisor to Hetero on the acquisition of the Penjerla manufacturing facility together with the land, plant and machinery in a slump sale from Johnson & Johnson Private Limited.
Hetero is a globally renowned, vertically integrated pharmaceutical organization, engaged in research and development, manufacturing, and marketing of high-quality chemical, generics and biologics medicines across diverse therapeutic areas. Backed by 30 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world. For more information on Hetero, please visit www.hetero.com.